



2nd Annual MDA Insights in Research Investor Summit (IRIS) for Neuromuscular Disease
All times listed are Central Daylight Time

Room Hermitage CD

| Sunday, March 13, 2022 | |
|---|--|
| 9:00 AM – 9:10 AM | Opening Remarks |
| Muscular Dystrophy Focused Opportunities | |
| 9:10 AM – 9:30 AM | <i>Regeneration from Within</i> Ryan Mitchell, PhD Satellos Bioscience Inc. |
| 9:30 AM – 9:50 AM | <i>MyoGene Bio's Gene Editing Therapy for Duchenne</i> Courtney Young, PhD MyoGene Bio |
| 9:50 AM – 10:10 AM | <i>MyoArete's Utrophin-Upregulation Small Molecules for Muscular Dystrophy</i> Tejvir S. Khurana, MD, PhD MyoArete |
| 10:10 AM – 10:30 AM | <i>A Novel Platform for Non-Viral Targeted Delivery of Full-Length Dystrophin to Dystrophic Muscle</i> Stanley C. Froehner, PhD Myosana Therapeutics, Inc |
| Break | |
| 10:30 AM – 11:00 AM | |
| 11:00 AM – 11:20 AM | <i>Ortholevo</i> Edward Ahn, PhD Ortholevo |
| 11:20 AM – 11:40 AM | <i>Innovating Therapies for Neuromuscular and Heart Diseases</i> Casey Childers, PhD. Kinea Bio |
| Other NMD Focused Opportunities | |
| 11:40 AM - 12:00 PM | <i>Myto Therapeutics</i> Gino Cortopassi, PhD Myto Therapeutics |
| 12:00 PM - 12:20 PM | <i>Novel Small Molecule Calcium Channel Gating Modifiers with Broad Therapeutic Potential at the NMJ</i> Stephen Meriney, PhD University of Pittsburgh |
| Lunch on Your Own | |

12:20 PM - 1:30 PM

ALS Focused Opportunities

1:30 PM - 1:50 PM

Clene Nanomedicine, a Novel Approach to Improving Neurological Function

Karen Ho, PhD
Clene Nanomedicine, Inc

1:50 PM - 2:10 PM

AcuraStem

Sam Alworth, PhD
AcuraStem

2:10 PM - 2:30 PM

Developing HDAC6 Inhibitors as Novel Therapeutics for ALS

Janice Kranz, PhD
Eikonizo Therapeutics, Inc

2:30 PM - 2:50 PM

Origent Data Sciences

David Ennist, PhD
Origent Data Sciences